Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionality is currently unavailable.

Rupal Satish Bhatt, M.D.

Co-Author

This page shows the publications co-authored by Rupal Bhatt and Prateek Khanna.
Connection Strength

0.912
  1. Gjyrezi A, Xie F, Voznesensky O, Khanna P, Calagua C, Bai Y, Kung J, Wu J, Corey E, Montgomery B, Mace S, Gianolio DA, Bubley GJ, Balk SP, Giannakakou P, Bhatt RS. Taxane resistance in prostate cancer is mediated by decreased drug-target engagement. J Clin Invest. 2020 Jun 01; 130(6):3287-3298.
    View in: PubMed
    Score: 0.242
  2. Chen CH, Bhasin S, Khanna P, Joshi M, Joslin PM, Saxena R, Amin S, Liu S, Sindhu S, Walker SR, Catalano P, Frank DA, Alper SL, Bhasin M, Bhatt RS. Study of Cathepsin B inhibition in VEGFR TKI treated human renal cell carcinoma xenografts. Oncogenesis. 2019 Feb 22; 8(3):15.
    View in: PubMed
    Score: 0.221
  3. Scelo G, Muller DC, Riboli E, Johansson M, Cross AJ, Vineis P, Tsilidis KK, Brennan P, Boeing H, Peeters PHM, Vermeulen RCH, Overvad K, Bueno-de-Mesquita HB, Severi G, Perduca V, Kvaskoff M, Trichopoulou A, La Vecchia C, Karakatsani A, Palli D, Sieri S, Panico S, Weiderpass E, Sandanger TM, Nøst TH, Agudo A, Quirós JR, Rodríguez-Barranco M, Chirlaque MD, Key TJ, Khanna P, Bonventre JV, Sabbisetti VS, Bhatt RS. KIM-1 as a Blood-Based Marker for Early Detection of Kidney Cancer: A Prospective Nested Case-Control Study. Clin Cancer Res. 2018 11 15; 24(22):5594-5601.
    View in: PubMed
    Score: 0.213
  4. Wang X, Solban N, Khanna P, Callea M, Song J, Alsop DC, Pearsall RS, Atkins MB, Mier JW, Signoretti S, Alimzhanov M, Kumar R, Bhasin MK, Bhatt RS. Inhibition of ALK1 signaling with dalantercept combined with VEGFR TKI leads to tumor stasis in renal cell carcinoma. Oncotarget. 2016 Jul 05; 7(27):41857-41869.
    View in: PubMed
    Score: 0.184
  5. Hu J, Schokrpur S, Archang M, Hermann K, Sharrow AC, Khanna P, Novak J, Signoretti S, Bhatt RS, Knudsen BS, Xu H, Wu L. A Non-integrating Lentiviral Approach Overcomes Cas9-Induced Immune Rejection to Establish an Immunocompetent Metastatic Renal Cancer Model. Mol Ther Methods Clin Dev. 2018 Jun 15; 9:203-210.
    View in: PubMed
    Score: 0.052
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.